KR102762352B1 - 약물 링커 화합물의 제조방법 - Google Patents

약물 링커 화합물의 제조방법 Download PDF

Info

Publication number
KR102762352B1
KR102762352B1 KR1020207018586A KR20207018586A KR102762352B1 KR 102762352 B1 KR102762352 B1 KR 102762352B1 KR 1020207018586 A KR1020207018586 A KR 1020207018586A KR 20207018586 A KR20207018586 A KR 20207018586A KR 102762352 B1 KR102762352 B1 KR 102762352B1
Authority
KR
South Korea
Prior art keywords
compound
formula
salt
alkyl
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207018586A
Other languages
English (en)
Korean (ko)
Other versions
KR20200094185A (ko
Inventor
소피 블랑샤르
제임스 코츠
Original Assignee
씨젠 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 씨젠 인크. filed Critical 씨젠 인크.
Priority to KR1020257002801A priority Critical patent/KR20250024092A/ko
Publication of KR20200094185A publication Critical patent/KR20200094185A/ko
Application granted granted Critical
Publication of KR102762352B1 publication Critical patent/KR102762352B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020207018586A 2017-11-30 2018-11-29 약물 링커 화합물의 제조방법 Active KR102762352B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257002801A KR20250024092A (ko) 2017-11-30 2018-11-29 약물 링커 화합물의 제조방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762593104P 2017-11-30 2017-11-30
US62/593,104 2017-11-30
PCT/US2018/063070 WO2019108797A1 (en) 2017-11-30 2018-11-29 Process for the preparation of drug linker compounds

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257002801A Division KR20250024092A (ko) 2017-11-30 2018-11-29 약물 링커 화합물의 제조방법

Publications (2)

Publication Number Publication Date
KR20200094185A KR20200094185A (ko) 2020-08-06
KR102762352B1 true KR102762352B1 (ko) 2025-02-05

Family

ID=66665808

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207018586A Active KR102762352B1 (ko) 2017-11-30 2018-11-29 약물 링커 화합물의 제조방법
KR1020257002801A Pending KR20250024092A (ko) 2017-11-30 2018-11-29 약물 링커 화합물의 제조방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257002801A Pending KR20250024092A (ko) 2017-11-30 2018-11-29 약물 링커 화합물의 제조방법

Country Status (15)

Country Link
US (2) US11612666B2 (https=)
EP (1) EP3717016A4 (https=)
JP (2) JP7402159B2 (https=)
KR (2) KR102762352B1 (https=)
CN (2) CN118271394A (https=)
AU (1) AU2018375412B2 (https=)
BR (1) BR112020010503A2 (https=)
CA (1) CA3082165A1 (https=)
EA (1) EA202091340A1 (https=)
IL (1) IL274757B2 (https=)
MA (1) MA51870A (https=)
MX (2) MX2020005565A (https=)
SG (1) SG11202004698RA (https=)
WO (1) WO2019108797A1 (https=)
ZA (1) ZA202003037B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3085001C (en) * 2019-05-20 2021-10-05 Mabplex International, Ltd. One-pot process for preparing intermediate of antibody-drug conjugate
WO2021077317A1 (zh) * 2019-10-23 2021-04-29 烟台迈百瑞国际生物医药股份有限公司 一种寡肽连接子中间体及其制备方法
BR112023018676A2 (pt) 2021-03-18 2023-10-10 Seagen Inc Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco
CN115873066A (zh) * 2022-07-27 2023-03-31 吉林省博大伟业制药有限公司 一种抗体偶联药物连接子的合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150105539A1 (en) 2012-05-15 2015-04-16 Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. Drug-Conjugates, Conjugation Methods, and Uses Thereof
WO2016046574A1 (en) 2014-09-25 2016-03-31 Antikor Biopharma Limited Biological materials and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214345B1 (en) * 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
EP2478912B1 (en) * 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
ES2382879T3 (es) * 2005-09-14 2012-06-14 Ucb Pharma, S.A. Conjugado de anticuerpo - polímero de peine.
JP2010503708A (ja) 2006-09-15 2010-02-04 エンゾン ファーマスーティカルズ インコーポレイテッド 多官能性リンカーを含む標的化ポリマープロドラッグ
EP2170805B1 (en) * 2007-06-21 2016-03-16 Amgen Inc. Methods of synthesizing cinacalcet and salts thereof
KR102356286B1 (ko) * 2011-05-27 2022-02-08 암브룩스, 인코포레이티드 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도
SI2941432T1 (en) 2012-12-07 2018-07-31 Vertex Pharmaceuticals Incorporated 2-AMINO-6-FLUORO-N- (5-FLUORO-4- (4- (4- (OXETHAN-3-YL) PIPERAZIN-1-CARBONYL) PIPERIDIN-1-YLIPRIDIN-3-YL) 1,5 ALFA) PYRIMIDINE-3-CARBOXAMIDE AS ATR KINAZE INHIBITOR
GB201309807D0 (en) 2013-05-31 2013-07-17 Pharma Mar Sau Antibody drug conjugates
US9533483B2 (en) 2014-09-26 2017-01-03 Kimberly-Clark Worldwide, Inc. Apparatus for and method of shaping and applying a segment to a moving web

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150105539A1 (en) 2012-05-15 2015-04-16 Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. Drug-Conjugates, Conjugation Methods, and Uses Thereof
WO2016046574A1 (en) 2014-09-25 2016-03-31 Antikor Biopharma Limited Biological materials and uses thereof

Also Published As

Publication number Publication date
MX2020005565A (es) 2020-08-20
IL274757B1 (en) 2025-12-01
CN111417408B (zh) 2024-04-23
US20240042052A1 (en) 2024-02-08
AU2018375412B2 (en) 2025-01-02
JP2021505542A (ja) 2021-02-18
WO2019108797A1 (en) 2019-06-06
ZA202003037B (en) 2023-12-20
US20200360532A1 (en) 2020-11-19
EP3717016A1 (en) 2020-10-07
KR20200094185A (ko) 2020-08-06
KR20250024092A (ko) 2025-02-18
AU2018375412A1 (en) 2020-05-28
SG11202004698RA (en) 2020-06-29
JP2023164652A (ja) 2023-11-10
JP7402159B2 (ja) 2023-12-20
JP7787859B2 (ja) 2025-12-17
MX2023009372A (es) 2023-08-16
MA51870A (fr) 2020-10-07
CN118271394A (zh) 2024-07-02
IL274757B2 (en) 2026-04-01
BR112020010503A2 (pt) 2020-10-20
CA3082165A1 (en) 2019-06-06
IL274757A (en) 2020-07-30
EP3717016A4 (en) 2021-09-01
EA202091340A1 (ru) 2020-10-16
US11612666B2 (en) 2023-03-28
CN111417408A (zh) 2020-07-14

Similar Documents

Publication Publication Date Title
JP7787859B2 (ja) 薬物リンカー化合物の調製のためのプロセス
TWI839055B (zh) 聚乙二醇化的藥物－連接劑及其中間體
JP7527787B2 (ja) グルクロニド薬物－リンカーの調製のためのプロセスおよびその中間体
ES2863923T3 (es) Formas cristalinas de la sal mesilato de derivado de piridinilaminopirimidina, métodos de preparación para las mismas, y aplicaciones de las mismas
HK40112601A (zh) 药物接头化合物的制备方法
HK40033820A (en) Process for the preparation of drug linker compounds
WO2025015586A1 (en) Drug conjugates of imidazoquinoline amine derivatives, compositions and methods thereof
EA044354B1 (ru) Способ получения соединений "лекарственное средство-линкер"
EA053235B1 (ru) Способ получения соединений "лекарственное средство-линкер"
HK40033820B (zh) 药物接头化合物的制备方法
EA047735B1 (ru) Способ получения пегилированных соединений лекарственный препарат-линкер и их промежуточных соединений
JP2020132531A (ja) 微小管重合を阻害する化合物及びこれらの抗体薬物複合体
HK40016637A (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
HK40009733A (en) Process for the preparation of pegylated drug-linkers and intermediates thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200626

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20211126

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20231124

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240725

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

AMND Amendment
PX0901 Re-examination

Patent event code: PX09012R01I

Patent event date: 20241023

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20241028

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

X701 Decision to grant (after re-examination)
PG1601 Publication of registration